Proteasome inhibitors in cancer therapy
EE Manasanch, RZ Orlowski - Nature reviews Clinical oncology, 2017 - nature.com
The ubiquitin proteasome pathway was discovered in the 1980s to be a central component
of the cellular protein-degradation machinery with essential functions in homeostasis, which …
of the cellular protein-degradation machinery with essential functions in homeostasis, which …
Single-cell profiling of tumour evolution in multiple myeloma—opportunities for precision medicine
Multiple myeloma (MM) is a haematological malignancy of plasma cells characterized by
substantial intraclonal genetic heterogeneity. Although therapeutic advances made in the …
substantial intraclonal genetic heterogeneity. Although therapeutic advances made in the …
Genomic profiling for clinical decision making in lymphoid neoplasms
With the introduction of large-scale molecular profiling methods and high-throughput
sequencing technologies, the genomic features of most lymphoid neoplasms have been …
sequencing technologies, the genomic features of most lymphoid neoplasms have been …
The multiple myelomas—current concepts in cytogenetic classification and therapy
Multiple myeloma (MM) is a plasma cell neoplasm that accounts for 2% of all haematological
malignancies and predominantly affects older individuals (with a median age at diagnosis of …
malignancies and predominantly affects older individuals (with a median age at diagnosis of …
Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy
We performed massively parallel sequencing of paired tumor/normal samples from 203
multiple myeloma (MM) patients and identified significantly mutated genes and copy number …
multiple myeloma (MM) patients and identified significantly mutated genes and copy number …
Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond
Despite enormous advances, management of multiple myeloma (MM) remains challenging.
Multiple factors impact the decision to treat or which regimen to use at MM …
Multiple factors impact the decision to treat or which regimen to use at MM …
Heterogeneity of genomic evolution and mutational profiles in multiple myeloma
Multiple myeloma is an incurable plasma cell malignancy with a complex and incompletely
understood molecular pathogenesis. Here we use whole-exome sequencing, copy-number …
understood molecular pathogenesis. Here we use whole-exome sequencing, copy-number …
[HTML][HTML] Evolution and impact of subclonal mutations in chronic lymphocytic leukemia
Clonal evolution is a key feature of cancer progression and relapse. We studied intratumoral
heterogeneity in 149 chronic lymphocytic leukemia (CLL) cases by integrating whole-exome …
heterogeneity in 149 chronic lymphocytic leukemia (CLL) cases by integrating whole-exome …
Co-evolution of tumor and immune cells during progression of multiple myeloma
Multiple myeloma (MM) is characterized by the uncontrolled proliferation of plasma cells.
Despite recent treatment advances, it is still incurable as disease progression is not fully …
Despite recent treatment advances, it is still incurable as disease progression is not fully …
Cancer heterogeneity: implications for targeted therapeutics
Developments in genomic techniques have provided insight into the remarkable genetic
complexity of malignant tumours. There is increasing evidence that solid tumours may …
complexity of malignant tumours. There is increasing evidence that solid tumours may …